About Us
The science behind DNA Halo® didn't come from a marketing team. It came from physicians and researchers who saw a problem no one else was solving.
Our Story
Cora Nutraceuticals was founded on a simple but urgent observation: the people most exposed to ionizing radiation — the physicians, radiologists, flight crews, first responders, military and technologists who work with it every day — had no clinically validated tool to protect themselves at the cellular level.
Lead aprons block scatter radiation. Dosimeters measure exposure. But nothing on the market was designed to address what radiation actually does inside the body: break DNA.
Dr. Kieran Murphy, MD, one of the world's foremost interventional neuroradiologists, spent years watching colleagues accumulate occupational radiation exposure with no meaningful mitigation beyond distance and shielding. The published data on brain tumor clusters among interventional radiologists, cardiovascular disease linked to chronic low-dose exposure, and radiation-induced cataracts in pilots told a story the industry wasn't talking about. Dr. Murphy decided to do something about it.
The result — developed in collaboration with researchers at Dalhousie University, the University of Toronto, and McMaster University, and validated through peer-reviewed human clinical trials — is DNA Halo®: a patented nutraceutical formulation proven to reduce DNA strand breaks from ionizing radiation and oxidative stress.
Cora Nutraceuticals exists to bring that science to the people who need it most — and to everyone who understands the importance of cellular health.
Our Leadership Team
Kieran Murphy
MB BAO BCH FRCPC FSIR
Co-founder & Chief Science Officer
Dr. Kieran Murphy is a physician and interventional neuroradiologist at Toronto Western Hospital and one of the most decorated innovators in modern medicine. He graduated from the Royal College of Surgeons in Dublin, Ireland, completed his Radiology residency and Neuroradiology fellowship at the University of Michigan, Ann Arbor, and his Interventional Neuroradiology fellowship at the University of Geneva. Prior to joining Toronto Western, he led the Division of Interventional Neuroradiology at Johns Hopkins for a decade.
Over the course of his career, Dr. Murphy has authored more than 176 peer-reviewed publications, filed over 80 patents on new medical devices, and founded eight medical device companies. He has mentored more than 100 undergraduate, graduate, and medical trainees, and his clinical focus spans spine augmentation, radiofrequency ablation of bone metastatic disease, and — most relevantly to DNA Halo® — antioxidant use in radiation injury reduction.
The science behind DNA Halo® is Dr. Murphy's science. He identified the problem, designed the research program, co-authored the published human clinical trials, and led the patent filings that now protect the formula across 11 national jurisdictions.
Dr. Murphy was awarded the Society of Interventional Radiology Innovator of the Year in 2015, nominated for the 2016 Manning Innovation Award, and received the 2019 American Society of Vascular Interventional Technology Award for Innovation and Mentorship.
William (Bill) Attinger
CEO & Co-founder
Bill Attinger brings more than 34 years of experience growing, financing, and developing early-stage and high-growth companies across a broad range of industries. His background spans investment banking at Morgan Stanley — where he focused on healthcare finance and structured more than $1 billion in publicly offered securities — private equity, venture capital, and operational leadership as a founder or co-founder of six companies.
Bill's work in healthcare finance began in the early 1990s, serving some of the largest teaching hospitals and healthcare systems in the United States. His derivative research has been published in the Financial Analysts Journal. Over the past decade he has served as Managing Partner and Investment Strategist for investing partnerships under the Global Trust / Global Community Capital umbrella, capitalizing more than 30 companies across AI, medical devices, supply chain, public safety technology, and more.
At Cora Nutraceuticals, Bill is responsible for commercialization strategy, capital formation, and building the distribution network that brings DNA Halo® from the laboratory to the people who need it.
Bill earned his Bachelor's Degree in Economics and his Master's Degree in Finance from the University of Alabama.
Bryan Sigler
COO & Co-founder
Bryan Sigler brings more than 30 years of leadership experience across healthcare, medical devices, and highly regulated industries. As Chief Operating Officer of Cora Nutraceuticals, he oversees manufacturing, compliance, regulatory affairs, and operational execution — ensuring that DNA Halo® is produced and delivered to the standards its clinical pedigree demands.
Bryan's background spans roles as Chief Operating Officer at Control Flo Medical (where he led an FDA De Novo application process), Chief Development Officer at Sanctuary Systems (government agency liaison and international contract negotiation), Director of the Chemical Dependency Center at Baytown Medical Center, and Instructor of Health Administration at Florida Atlantic University. His operational experience also includes a high-performance automotive manufacturing role under license from Carroll Shelby — a testament to his versatility in precision, regulated environments.
Bryan holds an MBA from Louisiana Tech University and 66 doctoral hours in Administration-Health Services from the University of Alabama, Birmingham.
Scientific Advisory Board
John Kaufman, MD, MS
Dr. Kaufman is Director of the Dotter Institute and past President of the Society of Interventional Radiology. His clinical interests include aortic aneurysms, venous diseases, vascular malformations, and image-guided treatment of liver cancers and uterine fibroids. He has authored or co-authored more than 200 publications including five textbooks, and serves as Co-editor of Techniques in Vascular and Interventional Radiology and Associate Editor of CardioVascular and Interventional Radiology.
Dr. Kaufman has been honored as a Gold Medalist of the Society of Interventional Radiology, a Distinguished Fellow of the Cardiovascular and Interventional Radiology Society of Europe, and a Distinguished Alumnus of Boston University School of Medicine.
Michael Dake, MD
A graduate of Harvard College and Baylor College of Medicine, Dr. Dake is board certified in internal medicine, pulmonary disease, diagnostic radiology, and vascular and interventional radiology. He holds an international reputation for revolutionary work in vascular health, with more than 300 peer-reviewed articles and 100 book chapters to his name. His publications in Nature Medicine have been cited more than 1,000 times; his papers in the New England Journal of Medicine more than 1,500 times. In total, Dr. Dake's contributions to the medical literature have earned more than 30,000 citations — placing him among the top scientists in his field. He holds 31 U.S. patents and has founded five companies.
Lindsay Machan, MD
Dr. Machan is an interventional radiologist at Vancouver Hospital and Associate Professor of Radiology at the University of British Columbia. His professional interests include endovascular vein therapy and local therapy of restenosis. He is co-founder of Angiotech Pharmaceuticals — which developed and licensed the paclitaxel-coated stent — and Ikomed Technologies, which develops methods for reducing radiation dose during fluoroscopy.
Dr. Machan is a founder of CIRA (Canadian Interventional Radiology Association), co-author of Interventional Procedures (the largest-selling interventional textbook worldwide), and has authored over 140 patents. He is an active angel investor and sits on numerous commercial and scientific advisory boards across Canada and the United States.